

Financial Tear Sheet

Corporate Profile

Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of FP187, a proprietary formulation of dimethyl fumarate (DMF) for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the recent Settlement and License Agreement and received from Biogen a non-refundable cash fee of \$1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on sales of Tecfidera® or other DMF products for MS, dependent on, among other things, successfully appealing the U.S. interference and a favorable outcome in Europe with respect to the EP2801355 opposition proceeding.

Stock Performance

FWP (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price **\$4.36**

Change (%) ▲ 0.04 (0.93%)

Volume 2,732

52 Week Low \$3.04

Market Cap \$205,722,236

Rolling EPS 3.80

PE Ratio 1.1363

Shares Outstanding 47,183,999

Data as of 01/19/18 4:00 p.m. ET



Recent Headlines

12/21/17

Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit

11/29/17

Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018

11/27/17

Forward Pharma to Participate in Investor Conferences in December

Upcoming Events

Date	Title
02/14/18 through 02/15/18	Forward Pharma A/S at LEERINK Partners 7th Annual Global Healthcare Conference Location New York, NY

SEC Filings

Filing Date	Form	Corporate Governance	
01/05/18	6-K	Claus Bo Svendsen, MD, PhD	CEO
01/03/18	SC 13G	Peder Møller Andersen, MD	COO
12/21/17	6-K		
12/04/17	6-K		

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources